Recognan solution for injection 500mg / 4ml, No. 5

• Ischemic stroke (acute period);

• ischemic and hemorrhagic stroke (recovery period);

• traumatic brain injury (acute and recovery period);

• cognitive impairment in degenerative and vascular diseases of the brain.

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

When taken orally - 200-300 mg 3 times / day.

IV for strokes and traumatic brain injury in the acute period - 1-2 g / day, depending on the severity of the disease for 3-7 days, followed by a transition to the / m introduction or ingestion.

W / m - 0.5-1 g / day.

Active ingredient: citicoline sodium - 522.5 mg, which corresponds to the content of citicoline - 500 mg

Excipients: hydrochloric acid or sodium hydroxide - up to pH 6.5-7.5, water d / i - up to 4 ml.

• Vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);

• children and adolescents up to 18 years old;

• hypersensitivity to citicoline.

Clinical and pharmacological group: Nootropic drug

Pharmaco-therapeutic group: Nootropic agent

pharmachologic effect

Nootropic agent. Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: it helps to restore damaged cell membranes, inhibits the action of phospholipases, preventing the excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.

In the acute period of stroke, it reduces the volume of damaged tissue, improves cholinergic transmission.

In traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms.

Citicoline improves the symptoms observed during hypoxia: memory impairment, emotional lability, lack of initiative, difficulties in performing daily activities and self-care. Effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.

Pharmacokinetics

Since citicoline is a natural compound that is found in the body, a classical pharmacokinetic study cannot be performed due to the complexity of the quantitative determination of exogenous and endogenous citicoline.

Indications

• Ischemic stroke (acute period);

• ischemic and hemorrhagic stroke (recovery period);

• traumatic brain injury (acute and recovery period);

• cognitive impairment in degenerative and vascular diseases of the brain.

Dosage regimen

The method of application and dosage regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the used dosage form of a particular drug with the indications for use and the dosage regimen.

When taken orally - 200-300 mg 3 times / day.

IV for strokes and traumatic brain injury in the acute period - 1-2 g / day, depending on the severity of the disease for 3-7 days, followed by a transition to the / m introduction or ingestion.

W / m - 0.5-1 g / day.

Side effect

From the nervous system: insomnia, headache, dizziness, agitation, tremors, numbness in paralyzed limbs.

From the digestive system: nausea, decreased appetite, changes in the activity of liver enzymes.

Allergic reactions: rash, itching of the skin, anaphylactic shock.

Others: fever; in some cases - a short-term hypotensive effect, stimulation of the parasympathetic nervous system.

Contraindications for use

• Vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system);

• children and adolescents up to 18 years old;

• hypersensitivity to citicoline.

Application during pregnancy and lactation

During pregnancy, use is possible only if the expected benefit of therapy to the mother outweighs the potential risk to the fetus.

If it is necessary to use citicoline during lactation, the issue of stopping breastfeeding should be resolved, since there are no data on the excretion of citicoline in breast milk.

Application in children

Contraindicated in children and adolescents under 18 years of age.

Use in elderly patients

Application is possible according to indications.

special instructions

Citicoline should not be used concurrently with drugs containing meclofenoxate.

Drug interactions

Citicoline enhances the effects of L-dihydroxyphenylalanine.

Contacts for inquiries

GEROPHARM LLC (Russia)